Development and validation of a new high-performance liquid chromatography method for the determination of gliclazide and repaglinide in pharmaceutical formulations

A new high-performance liquid chromatography method was developed and validated for the quantitation of gliclazide and repaglinide in pharmaceutical formulations. Determination was performed using a LiChroCART RP-18 column, a mobile phase containing acetonitrile-phosphate buffer (pH 2.1; 60 + 40, v/v), and ultraviolet (UV) detection at 225 nm. Repaglinide was used as an internal standard for gliclazide determination and gliclazide for repaglinide assay. The method was validated with respect to linearity, precision, robustness, ruggedness, accuracy, and specificity. The calibration graphs ranged from 0.015 to 0.09 mg/mL for gliclazide and 0.06 to 0.36 mg/mL for repaglinide. Intra- and interday relative standard deviation values for the standard solutions were 0.70 and 1.01% for gliclazide and 0.78 and 0.93% for repaglinide, respectively. Total recoveries of gliclazide and repaglinide from the laboratory-prepared mixtures were 99.82 +/- 0.58 and 101.50 +/- 0.46% for gliclazide and repaglinide, respectively [mean +/- standard deviation (SD)]. In forced degradation studies, the effect of acid, base, oxidation, UV light, and temperature on both drugs was also investigated. Finally, the method was applied for the quality control of commercial gliclazide and repaglinide tablets. Total recovery was 100.40 +/- 0.35 and 104.46 +/- 0.23% for gliclazide and repaglinide, respectively (mean +/- SD).     

A new rapid and economic liquid chromatographic method for simultaneous determination of meglitinides with metformin: application in the presence of metformin and repaglinide impurities and related compounds

A new liquid chromatographic method was developed for simultaneous determination of the widely used oral antidiabetic, metformin hydrochloride with antidiabetics comprising the meglitinides class in bulk, laboratory-prepared mixtures and pharmaceutical products. It was applied in the presence of metformin-reported impurity (1-cyanoguanidine). It was also applied for the determination of repaglinide in the presence of its related compounds. Chromatographic separation was achieved with isocratic elution mode using a mobile phase of acetonitrile: 0.01 M sodium dihydrogen phosphate (pH: 2.8) (67:33; v/v) flowing through a LiChrospher NH₂ (amino) Agilent^® column (250 × 4.6 mm—5 µm) at a rate of 0.8 mL/min at ambient temperature in a run time of 4 min. UV detection was carried out at 220 nm. The method was validated according to International Conference on Harmonization guidelines. Linearity, accuracy and precision were satisfactory over concentration ranges (µg/mL): 3.5–350 for metformin hydrochloride, 14–140 for nateglinide, 1–100 for mitiglinide calcium and 0.1–100 for repaglinide. Coefficients of determination were ?0.99 for all analytes. Limits of quantification were found (in µg/mL): 0.06, 0.08, 0.198 and 0.029 for metformin hydrochloride, nateglinide, mitiglinide calcium and repaglinide, respectively. The present method was found to be rapid, selective, economic and simple in operation satisfying the chromatographers’ needs for quality assessment of pharmaceutical products.     

A comparative study of first-derivative spectrophotometry and column high-performance liquid chromatography applied to the determination of repaglinide in tablets and for dissolution testing

A fast and reliable method for the determination of repaglinide is highly desirable to support formulation screening and quality control. A first-derivative UV spectroscopic method was developed for the determination of repaglinide in tablet dosage form and for dissolution testing. First-derivative UV absorbance was measured at 253 nm. The developed method was validated for linearity, accuracy, precision, limit of detection (LOD), and limit of quantitation (LOQ) in comparison to the U.S. Pharmacopeia (USP) column high-performance liquid chromatographic (HPLC) method. The first-derivative UV spectrophotometric method showed excellent linearity [correlation coefficient (r) = 0.9999] in the concentration range of 1-35 microg/mL and precision (relative standard deviation < 1.5%). The LOD and LOQ were 0.23 and 0.72 microg/mL, respectively, and good recoveries were achieved (98-101.8%). Statistical comparison of results of the first-derivative UV spectrophotometric and the USP HPLC methods using the t-test showed that there was no significant difference between the 2 methods. Additionally, the method was successfully used for the dissolution test of repaglinide and was found to be reliable, simple, fast, and inexpensive.     

Dynamic Metabolic Profiling of Urine From Type 2 Diabetic KK-Ay Mice Treated with Repaglinide by GC-MS

Repaglinide is a short-acting insulin secretagogue, commonly used for the treatment of type 2 diabetes. In this paper, metabolomics were first applied to research of dynamic urine metabolic profiling and biomarkers of type 2 diabetic KK-A^y mice treated with repaglinide based on GC-MS. Twenty diabetic KK-A^y mice were randomly assigned to four groups and fed with repaglinide for 6, 9, 12, and 14 weeks, respectively. Five C57BL/6 J mice were used as the healthy control group and fed with water as contrast. The PCA scores plot of the identified 41 metabolites showed that as treating time went on, the diabetic groups got closer to the healthy group. Furthermore, five marker metabolites, d-Glucose, d-Galactose, 1,5-Anhydro-d-glucitol, myo-inositol and tartaric acid were screened out, which have similar change footprints of the whole metabolic profiles. The results demonstrated that repaglinide not only regulates the sugars and polyalcohol but also the organic acid in the organism. This work has illustrated the potential of metabolomics to disease diagnosis, pharmacology, and pharmacodynamics research.     

Synthesis and characterization of the inclusion complex between repaglinide and sulfobutylether-β-cyclodextrin (Captisol®)

An inclusion complex between repaglinide and a cyclodextrin derivative, 7-sulfobutylether-β-cyclodextrin (Captisol^®) was synthesized and characterized taking into account its possible benefits regarding the solubility, thus the bioavailability of repaglinide (an oral antidiabetic, carbamoyl methyl benzoic acid, practically insoluble in water, used for the treatment of type II diabetes mellitus). In order to establish the optimal conditions for the synthesis, phase-solubility studies were performed. Their results (A_L type phase-solubility diagram), as well as the chromatographic retention behavior of repaglinide in the presence of Captisol^® indicated that an 1:1 inclusion complex is formed. The estimated apparent stability constant, according to the Higuchi-Connors method is 530 M^?1. These data were confirmed by ¹H-NMR, IR, DTA of the inclusion complex prepared through lyophilization.     

Determination of repaglinide in pharmaceutical formulations by HPLC with UV detection.

A simple, precise and rapid RP-HPLC method was developed for the determination of repaglinide in pharmaceutical dosage forms. The method was carried out on a Shim-pack, RP-C18 column using a mixture of methanol: 0.1% v/v triethylamine (pH adjusted to 7 with orthophosphoric acid) and detection was done at 235 nm using nimesulide as internal standard. The linearity range was 0.1 to 0.5 microg/ml. The intra-day and inter-day precision were in the range of 0.48 to 1.01 and 0.15 to 1.15, respectively.     

Novel repaglinide complexes with manganese(II), iron(III), copper(II) and zinc(II): Spectroscopic,DFT characterization and electrochemical behaviour

Novel transition metal complexes with the repaglinide ligand [2-ethoxy-4-[N-[1-(2piperidinophenyl)-3-methyl-1-1butyl] aminocarbonylmethyl]benzoic acid] (HL) are prepared from chloride salts of manganese(II), iron(III), copper(II), and zinc(II) ions in water-alcoholic media. The mononuclear and non-electrolyte [M(L)₂(H₂O)₂]?nH₂O (M = Mn²⁺, n = 2, M = Cu²⁺, n = 5 and M = Zn²⁺, n = 1) and [M(L)₂(H₂O)(OH)]?H₂O (M = Fe³⁺) complexes are obtained with the metal:ligand ratio of 1:2 and the L-deprotonated form of repaglinide. They are characterized using the elemental and molar conductance. The infrared, ¹H and ¹³C NMR spectra show the coordination mode of the metal ions to the repaglinide ligand. Magnetic susceptibility measurements and electronic spectra confirm the octahedral geometry around the metal center. The experimental values of FT-IR, ¹H, NMR, and electronic spectra are compared with theoretical data obtained by the density functional theory (DFT) using the B3LYP method with the LANL2DZ basis set. Analytical and spectral results suggest that the HL ligand is coordinated to the metal ions via two oxygen atoms of the ethoxy and carboxyl groups. The structural parameters of the optimized geometries of the ligand and the studied complexes are evaluated by theoretical calculations. The order of complexation energies for the obtained structures is as follows:

$$Fe(III) complex < Cu(II) complex < Zn(II) complex < Mn(II) complex.$$

The redox behavior of repaglinide and metal complexes are studied by cyclic voltammetry revealing irreversible redox processes. The presence of repaglinide in the complexes shifts the reduction potentials of the metal ions towards more negative values.

     

Synthesis of Repaglinide Congeners

This report describes a synthesis of two potent impurities of repaglinide, benzyl repaglinide 1 and repaglinide isomer 2, from commercially available raw materials: 2-fluoro benzonitrile, (S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butylamine (5), and 3-ethoxy-[4-(ethoxycarbonyl)phenyl]acetic acid (7). These impurities are the crucial components in determining the quality of the drug substance, repaglinide, during its manufacturing.     

Analysis of repaglinide enantiomers in pharmaceutical formulations by capillary electrophoresis using 2,6-di-o-methyl-β-cyclodextrin as a chiral selector

This study used the general applicability of 2,6-didi-o-methyl-β-cyclodextrin (DM-β-CD) as the chiral selector in capillary electrophoresis for fast and efficient chiral separation of repaglinide enantiomers. A systematic study of the parameters affecting separation was performed with UV detection at 243 nm. The optimum conditions were determined to be 1.25% (w/v) DM-β-CD in 20 mM sodium phosphate (pH 2.5) as the running buffer and separation voltage at 20 kV. DM-β-CD had the best enantiomer resolution properties under the tested conditions, whereas other β-cyclodextrins showed inferior performances or no performance. The proposed method had a linear calibration curve in the concentration range of 12.5-400 μg/mL. The limit of detection was 100 ng/mL. The intra-day and inter-day precisions were 2.8 and 3.2%, respectively. Recoveries of 97.9-100.9% were obtained. The proposed method was fast and convenient, and was determined to be efficient for separating enantiomers and applicable for analyzing repaglinide enantiomers in quality control of pharmaceutical production.     

超高效液相色谱-四极杆/静电场轨道阱高分辨质谱快速筛查及定量分析保健品中11种非法添加降糖药物

基于超高效液相色谱-四极杆/静电场轨道阱质谱建立了保健品中11种非法添加化学降糖药(那格列奈、盐酸吡格列酮、格列喹酮、格列齐特、格列吡嗪、格列本脲、盐酸二甲双胍、瑞格列奈、盐酸苯乙双胍、盐酸罗格列酮、格列美脲)的快速筛查和定量分析方法。样品采用甲醇提取,C18色谱柱(100 mm×4.6 mm, 2.7 μm)分离,用10 mmol/L乙酸铵水溶液和乙腈进行梯度洗脱,正离子模式扫描。化合物一级质谱的分辨率为70000,二级质谱分辨率为17500。实验结果表明,11种化合物在0.005~0.5 mg/L范围内具有良好的线性(线性相关系数均大于0.99),各降糖类药物检出限为2.7~5.1 μg/kg,回收率为87.3%~98.3%,相对标准偏差为2.18%~5.21%。本方法具有准确、简便、快速的特点,可用于降糖类保健品中11种降糖药物的定性筛查和定量分析。     

Uncertainty evaluation for the determination of repaglinide in human plasma by LC–MS/MS

Measurement uncertainty although introduced to medical laboratories some years ago, this concept is not familiar to all medical researchers, especially for the measurement of biological samples. Therefore, it is important to highlight the evaluation and expression of measurement uncertainty using a practical example. In accordance with published procedures for evaluating and expressing uncertainty, we analyzed the sources of uncertainty in the determination of repaglinide in human plasma using liquid chromatography–tandem mass spectrometry (LC–MS/MS). We investigated each component of uncertainty and calculated the combined and expanded uncertainties. We evaluated the uncertainty associated with repeatability, weighing, purity, solution and sample preparation, recovery, calibration fitting, and temperature. The expanded uncertainty for low, medium, and high concentrations of repaglinide was 0.090, 0.25, and 3.16 ng/mL, respectively (p = 95 %, k = 2). This example provides an important reference for the evaluation of uncertainty in biological sample determinations using LC–MS/MS and human plasma and will be helpful in explaining the reliability of test results.     

A Validated Chiral LC Method for the Enantiomeric Separation of Repaglinide on Amylose Based Stationary Phase

A simple, isocratic, normal phase chiral HPLC method was developed and validated for the enantiomeric separation of repaglinide, (S)-(+)-2-ethoxy-4-N [1-(2-piperidinophenyl)-3-methyl-1-butyl] aminocarbonylmethyl] benzoic acid, an antidiabetic in bulk drug substance. The enantiomers of repaglinide were resolved on a ChiralPak AD-H (amylose based stationary phase) column using a mobile phase consisting of n-hexane: 2-propanol:trifluoroacetic acid (95:5:0.2 v/v/v) at a flow rate of 1.0 mL min⁻¹. The resolution between the enantiomers was found to be not >3.5 in optimized method. The presence of trifluoroacetic acid in the mobile phase played an important role, in enhancing chromatographic efficiency and resolution between the enantiomers. The developed method was extensively validated and proved to be robust. The calibration curve for (R)-enantiomer showed excellent linearity over the concentration range of 900 ng mL⁻¹ (LOQ) to 6,000 ng mL⁻¹. The limit of detection and limit of quantification for (R)-enantiomer were 300 and 900 ng mL⁻¹, respectively. The percentage recovery of the (R)-enantiomer ranged between 98.3 and 101.05% in bulk drug samples of repaglinide. Repaglinide sample solution and mobile phase were found to be stable up to 48 h. The developed method was found to be enantioselective, accurate, precise and suitable for quantitative determination of (R)-enantiomer in bulk drug substance.     

Determination of antihyperglycemic drugs in nanomolar concentration levels by micellar electrokinetic chromatography with non-ionic surfactant

A method for the separation of six selected antihyperglycemic (antidiabetic) drugs (tolbutamide, gliclazide, glimepiride, glibenclamide, repaglinide, and glipizide) was developed with use of micellar electrokinetic chromatography. Two non-ionic poly(ethylene glycol)-based surfactants Genapol X-080 and Triton X-114 (reduced) were studied as neutral pseudostationary phases. High alkaline pH 10.0 was used to obtain negative charges of separated antidiabetic drugs and non-ionic surfactants were employed for selectivity alteration. Both non-ionic surfactants provided good selectivity at concentration 0.2% (v/v) in sodium borate buffer and the separation of six drugs was obtained within 5 min. An on-line preconcentration method based on reversed electrode polarity switching was employed for the determination of antihyperglycemic drugs in blood serum after acetonitrile protein precipitation. The limits of detection ranged from 20.8 nmol L⁻¹ for tolbutamide to 6.5 nmol L⁻¹ for glibenclamide, respectively.     

Reversal Diastereoselectivity Between the Organomagnesium and Organolithium Reagents on Chiral N-Tert-Butylsulfinylaldimines for the Preparation of Chiral Amines

The asymmetric synthesis of both the enantiomer of chiral amines from the single chiral source of N-tert-butylsulfinylaldimines (3) by simply changing the organometallic reagents through diastereoselective addition. An efficient enantioselective synthesis of chiral amines including (S)-3-methyl-1-(2-piperidin-1-yl-phenyl)butyl amine (6a), a key intermediate to prepare antidiabetic drug repaglinide (1), is reported.     

LC‐MS/MS‐ESI method for simultaneous quantitation of metformin and repaglinidie in rat plasma and its application to pharmacokinetic study in rats

A highly sensitive and specific LC‐MS/MS‐ESI method has been developed for simultaneous quantification of metformin (MFN) and repaglinide (RGN) in rat plasma (50 μL) using phenacetin as an internal standard (IS). Simple protein precipitation was used to extract MFN and RGN from rat plasma. The chromatographic resolution of MFN, RGN and IS was achieved with a mobile phase consisting of 0.2% formic acid in water–acetonitrile (1:1, v/v) with a time program flow gradient on a Chromolith RP‐18e column. The total chromatographic run time was 3.5 min and the elution of MFN, RGN and IS occurred at 1.64, 2.21 and 2.15 min, respectively. A linear response function was established for the range of concentrations 0.855–394 and 0.021–21.7 ng/mL for MFN and RGN, respectively. The intra‐ and inter‐day precision values for MFN and RGN met the acceptance as per FDA guidelines. MFN and RGN were stable in battery of stability studies viz., bench‐top, auto‐sampler and freeze–thaw cycles. The developed assay was applied to a pharmacokinetic study in rats. Copyright © 2012 John Wiley & Sons, Ltd.     

Electrochemical Determination of Carbofuran in Tomatoes by a Concanavalin A (Con A) Polydopamine (PDA)-Reduced Graphene Oxide (RGO)-Gold Nanoparticle (GNP) Glassy Carbon Electrode (GCE) with Immobilized Acetylcholinesterase (AChE)

A new biosensor method was developed to determine residual carbofuran in tomatoes in a rapid and convenient fashion based on immobilizing acetylcholinesterase (AChE) on an electrode modified by concanavalin A (Con A)/polydopamine (PDA)-reduced graphene oxide (RGO)-gold nanoparticle (GNP) nanocomposites. The specific binding between Con A and AChE was investigated by the Ellman method and cyclic voltammetry (CV). The synthesis of nanocomposites was monitored by ultraviolet-visible absorption spectroscopy, scanning electron microscopy (SEM), and electrochemical impedance spectroscopy (EIS). The results showed that, due to the specific binding and good electrical conductivity, the biosensor had 2.2 times higher bioactivity, leading to high sensitivity with a low Michaelis constant of 0.10?mM. Parameters that affect the response of the biosensor, such as the pH, enzyme loading, ionic concentration, and inhibition time, were optimized. When used for the detection of carbofuran, this biosensor showed a wide range of applicability from 5?µg/kg to 40?µg/kg with a detection limit of 0.012?µg/kg. In addition, the biosensor demonstrated good recovery values of 101% and 90% for 10?µg/kg and 100?µg/kg of the analyte, good stability, high repeatability, and a rapid detection time of 20?min for carbofuran in tomatoes, which provides significant advantages for future analysis.     

Simultaneous estimation of six anti-diabetic drugs--glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human plasma assay

This paper describes a convenient method for the separation and simultaneous determination of six anti-diabetic drugs viz., glibenclamide (GLB), gliclazide (GLC), glipizide (GLZ), pioglitazone (PGL), repaglinide (RPG) and rosiglitazone (RGL) in pharmaceutical formulations. Also, the assay has been shown applied to support quantification of the six anti-diabetic drugs in human plasma. The analytes were either injected directly onto the column after suitable dilution (pharmaceutical formulation analysis) or a simple extraction procedure, using acetonitrile, from human plasma spiked with anti-diabetic drugs and internal standard (IS). Ternary gradient elution at a flow rate of 1 mL/min was employed on an Intertisl ODS 3V column (4.6 x 250 mm, 5 microm) at ambient temperature. The mobile phase consisted of 0.01 m formic acid (pH 3.0), acetonitrile, Milli Q water and methanol. Celecoxib was used as an IS. The six anti-diabetic drugs were monitored at a wavelength of 260 nm. The nominal retention times of RGL, PGL, GLZ, GLC, GLB, IS and RGL were 11.4, 13.3, 14.8, 17.6, 20.78, 22.1 and 25.4 min, respectively. The assay developed for formulation analysis was found to be accurate and precise. The calibration curves ranged from 0.1 to 100 microg/mL for all analytes with the exception of GLB, where the range was 0.3-100 microg/mL. The plasma assay was validated for parameters such as specificity, accuracy and extraction recovery. The proposed method is simple, selective and can be extended for routine analysis of anti-diabetics in pharmaceutical preparations and in biological matrices.     

Effect of poly(vinyl acetate) (PVAc) on thermal behavior and mechanical properties of poly(3-hydroxybutyrate)/poly(propylene carbonate) (PHB/PPC) blends

To assess the compatibility of blends of synthetic poly(propylene carbonate) (PPC), with a natural bacterial poly(3-hydroxybutyrate) (PHB), a simple casting procedure of blend was used. poly(3-hydroxybutyrate)/poly(propylene carbonate) blends are found to be incompatible according to DSC and DMA analysis. In order to improve the compatibility and mechanical properties of PHB/PPC blends, poly(vinyl acetate) (PVAc) was added as a compatibilizer. The effects of PVAc on the thermal behavior, morphology, and mechanical properties of 70PHB/30PPC blend were investigated. The results show that the melting point and the crystallization temperature of PHB in blends decrease with the increase of PVAc content in blends, the loss factor changes from two separate peaks of 70PHB/30PPC blend to one peak of 70PHB/30PPC/12PVAc blend. It is also found that adding PVAc into 70PHB/30PPC blend can decrease the size of dispersed phase from morphology analysis. The result of tensile properties shows that PVAc can increase the tensile strength and Young’s modulus of 70PHB/30PPC blend, and both the elongation at break and the tensile toughness increase significantly with PVAc added into 70PHB/30PPC.     

聚丁二酸丁二醇酯与氯醚弹性体协同增韧改性聚乳酸多元共混体系

以来源于可再生资源聚丁二酸丁二醇酯(PBS)和氯醚橡胶(ECO)作为聚乳酸(PLA)的增韧改性剂,通过熔融共混的方法制备了PLA/PBS/ECO三元共混体系。动态力学分析和扫描电子显微镜结果表明,ECO促进了PBS和PLA之间的相容性。力学性能测试表明,ECO与PBS可实现对聚乳酸基体的协同增韧: PLA/PBS/ECO(70/20/10)显示出最优的拉伸性能,断裂伸长率高达270%;PLA/PBS/ECO(70/10/20)的冲击强度提高至23.7 kJ/m²,是纯聚乳酸的12倍。结合形态结构和冲击断面形貌分析表明ECO的存在可起到增容/增韧双重作用, 与柔性PBS产生良好的协同效应,有效改善聚乳酸材料的韧性。我们的研究表明,构造PLA-柔性生物聚酯和生物基弹性体多元共混体系是一种获得高性能生物基材料简单高效的手段。     

Extraction chromatographic study of aluminium(III) and mutual separation of aluminium(III), gallium(III), indium(III) and thallium(III) with N-n-octylaniline

A selective method has been developed for extraction chromatographic studies of aluminium(III) and its separation from several metal ions with a chromatographic column containing N-n-octylaniline (liquid anion exchanger) coated on silanized silica gel as a stationary phase. The aluminium(III) was quantitatively extracted with the 0.065 mol/L N-n-octylaninine from 0.013 to 0.05 mol/L sodium succinate at a flow rate of 1.0 mL/min. The extracted metal ion has been recovered by eluting with 25.0 mL of 0.05 mol/L hydrochloric acid and estimated spectrophotometrically with aurintricarboxylic acid. The effects of the acid concentration, the reagent concentration, the flow rate and the eluting agents have been investigated. The log-log plots of distribution coefficient (KdAl(III)) versus N-n-octylaniline concentrationin 0.005 and 0.007 mol/L sodium succinate gave theslopes 0.5 and 0.7 respectively and showed theprobable composition of theextracted species was 1:1 (metal to amine ratio) and the nature of extracted species is [RR''NH2+ Al succinate2-] org. .The extraction of aluminium(III) was carried out in the presence of various ions to ascertain the tolerance limit of individual ions. Aluminium(III) has been separated from multicomponent mixtures, pharmaceutical samples and synthetic mixtures corresponding to alloys. A scheme for mutual separation of aluminium(III), indium(III), gallium(III) and thallium(III) has been developed by using suitable masking agents. The method is fast, accurate and precise.